Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Leukemia
About this trial
This is an interventional treatment trial for Leukemia focused on measuring recurrent adult acute myeloid leukemia
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of t(8;21) acute myeloid leukemia (AML) Failed standard induction chemotherapy or stem cell transplantation (SCT) OR Relapsed after standard induction chemotherapy or SCT OR Refused or not a candidate for SCT or matched allogeneic sibling bone marrow transplantation or donor lymphocyte infusion OR Refused of not a candidate for autologous SCT or bone marrow transplantation No CNS leukemia PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 7 days Hematopoietic: Not specified Hepatic: AST or ALT no greater than 3 times upper limit of normal (ULN) Bilirubin no greater than 3 times ULN No hepatic disease that would preclude study Renal: Creatinine no greater than 2 mg/dL Creatinine clearance at least 60 mL/min No renal disease that would preclude study Cardiovascular: No cardiac disease that would preclude study No New York Heart Association class III or IV heart disease No myocardial infarction within past 8 weeks Other: No active infection except cystitis Not pregnant or nursing No altered mental status or seizure disorder No other serious disease that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: At least 3 weeks since prior investigational antineoplastic drugs
Sites / Locations
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
- National Heart, Lung, and Blood Institute
- Mount Sinai Medical Center, NY
- University of Pittsburgh Cancer Institute